Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Influence of the vitreomacular interface on the progression of diabetic macular edema after treatment with intravitreal injection of vascular endothelial growth factor inhibitors
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Non-PVD subjects | Patients with no PVD on SD-OCT at basal visit |
| |
| PVD subjects | Patients with PVD on SD-OCT at basal visit |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intravitreal Ranibizumab injection | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in best-corrected visual acuity | One year |
| Measure | Description | Time Frame |
|---|---|---|
| Change in central macular thickness | One year | |
| Number of ranibizumab injections | One year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with diabetic macular edema
Not provided
Not provided
Not provided
Not provided